FAM13C

Summary

FAM13C (family with sequence similarity 13 member C, HGNC:19371) is a protein-coding gene on chromosome 10q21.1, encoding Protein FAM13C (Q8NE31).

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 87 total
• MANE Select transcript: NM_198215

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19371
Approved symbol	FAM13C
Name	family with sequence similarity 13 member C
Location	10q21.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000148541
Ensembl biotype	protein_coding
Entrez	220965

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 14 protein_coding, 4 protein_coding_CDS_not_defined, 3 nonsense_mediated_decay, 2 retained_intron

ENST00000422313, ENST00000435852, ENST00000468696, ENST00000468840, ENST00000470220, ENST00000477101, ENST00000489341, ENST00000503444, ENST00000507568, ENST00000507862, ENST00000510215, ENST00000512919, ENST00000513377, ENST00000611933, ENST00000614220, ENST00000618427, ENST00000618804, ENST00000619059, ENST00000621119, ENST00000622363, ENST00000920262, ENST00000951023, ENST00000951024

RefSeq mRNA: 16 — MANE Select: NM_198215 NM_001001971, NM_001143773, NM_001166698, NM_001347840, NM_001347842, NM_001347843, NM_001347844, NM_001347845, NM_001347846, NM_001347847, NM_001347848, NM_001347849, NM_001347850, NM_001347851, NM_001347852, NM_198215

CCDS: CCDS31207, CCDS44406, CCDS53538, CCDS7255, CCDS86096

Canonical transcript exons

ENST00000618804 — 14 exons

Exon	Start	End
ENSE00003471576	59302801	59302864
ENSE00003512081	59268553	59268691
ENSE00003514215	59264085	59264166
ENSE00003516304	59262434	59262645
ENSE00003530304	59251575	59251676
ENSE00003554592	59252799	59252998
ENSE00003571820	59323988	59324106
ENSE00003594035	59269899	59270109
ENSE00003609136	59355887	59355943
ENSE00003641366	59352270	59352474
ENSE00003646858	59283363	59283447
ENSE00003673785	59254348	59254443
ENSE00003716347	59246133	59247737
ENSE00003738734	59362399	59362549

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 97.43.

FANTOM5 (CAGE): breadth broad, TPM avg 6.1554 / max 219.3556, expressed in 725 samples.

FANTOM5 promoters (16 alternative TSS)

Promoter ID	TPM avg	Samples expressed
109448	4.4829	681
109454	0.3214	93
109457	0.2312	90
109450	0.1671	100
109458	0.1554	90
109444	0.1321	48
109456	0.1188	65
109451	0.0822	50
109449	0.0798	50
109443	0.0796	52

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus callosum	UBERON:0002336	97.43	gold quality
inferior vagus X ganglion	UBERON:0005363	97.11	gold quality
subthalamic nucleus	UBERON:0001906	96.33	gold quality
medulla oblongata	UBERON:0001896	96.18	gold quality
pons	UBERON:0000988	95.91	gold quality
medial globus pallidus	UBERON:0002477	95.90	gold quality
superior vestibular nucleus	UBERON:0007227	95.56	gold quality
globus pallidus	UBERON:0001875	95.36	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.13	gold quality
endothelial cell	CL:0000115	94.67	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.60	gold quality
spinal cord	UBERON:0002240	94.30	gold quality
substantia nigra pars compacta	UBERON:0001965	94.15	gold quality
postcentral gyrus	UBERON:0002581	93.66	gold quality
sural nerve	UBERON:0015488	93.61	gold quality
ventral tegmental area	UBERON:0002691	93.48	gold quality
parietal lobe	UBERON:0001872	93.34	gold quality
parietal pleura	UBERON:0002400	92.57	gold quality
entorhinal cortex	UBERON:0002728	92.07	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.71	gold quality
dorsal plus ventral thalamus	UBERON:0001897	91.26	gold quality
lateral globus pallidus	UBERON:0002476	91.14	gold quality
superior frontal gyrus	UBERON:0002661	91.02	gold quality
temporal lobe	UBERON:0001871	90.93	gold quality
amygdala	UBERON:0001876	90.73	gold quality
prefrontal cortex	UBERON:0000451	90.63	gold quality
Ammon’s horn	UBERON:0001954	90.61	gold quality
calcaneal tendon	UBERON:0003701	90.49	gold quality
visceral pleura	UBERON:0002401	89.94	gold quality
biceps brachii	UBERON:0001507	89.53	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	31.62
E-GEOD-135922	yes	29.48
E-ANND-3	yes	4.63
E-MTAB-6678	no	2.42

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

156 targeting FAM13C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910

Literature-anchored findings (GeneRIF, showing 1)

• the results of our study demonstrate that expression of FAM13C is an independent prognostic marker in prostate cancer. (PMID:28415558)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fam13c	ENSMUSG00000043259
rattus_norvegicus	Fam13c	ENSRNOG00000000275
drosophila_melanogaster	CG6424	FBGN0028494

Paralogs (2): FAM13B (ENSG00000031003), FAM13A (ENSG00000138640)

Protein

Protein identifiers

Protein FAM13C — Q8NE31 (reviewed: Q8NE31)

All UniProt accessions (8): Q8NE31, A0A087X0M7, A0A087X1H9, A0A087X216, A0A087X2G4, B7Z2K3, D6RIX4, H0YGW3

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the FAM13 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q8NE31-1	1	yes
Q8NE31-2	2
Q8NE31-3	3
Q8NE31-4	4
Q8NE31-5	5

RefSeq proteins (16): NP_001001971, NP_001137245, NP_001160170, NP_001334769, NP_001334771, NP_001334772, NP_001334773, NP_001334774, NP_001334775, NP_001334776, NP_001334777, NP_001334778, NP_001334779, NP_001334780, NP_001334781, NP_937858* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR039102	FAM13	Family
IPR059029	FAM13A_dom	Domain

Pfam: PF26116

UniProt features (20 total): region of interest 6, splice variant 5, modified residue 4, compositionally biased region 3, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NE31-F1	61.67	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 131, 238, 385, 386

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 119 (showing top): GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, chr10q21, RACCACAR_AML_Q6, MORF_EPHA7, AACTTT_UNKNOWN, RYTTCCTG_ETS2_B, SABATES_COLORECTAL_ADENOMA_DN, AML1_01, CUI_TCF21_TARGETS_2_DN, DBP_Q6, MORF_IL9, MORF_DCC, ETF_Q6, OSF2_Q6, IRF2_01

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

444 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAM13C	SRD5A2	P31213	614
FAM13C	AZGP1	P25311	571
FAM13C	GSTM2	P28161	507
FAM13C	SFRP4	Q6FHJ7	507
FAM13C	TPX2	Q9ULW0	506
FAM13C	KLK2	P20151	506
FAM13C	TPM2	P06468	491
FAM13C	FLNC	Q14315	479
FAM13C	UMODL1	Q5DID0	472
FAM13C	SDAD1	Q9NVU7	471
FAM13C	CPXM2	Q8N436	452
FAM13C	LGALSL	Q3ZCW2	448
FAM13C	MSLNL	Q96KJ4	429
FAM13C	FAM131C	Q96AQ9	427
FAM13C	ATP5F1E	P56381	418
FAM13C	BGN	P13247	418

IntAct

51 interactions, top by confidence:

A	B	Type	Score
FAM13C	KIF2A	psi-mi:“MI:0915”(physical association)	0.670
FAM13C	CCDC172	psi-mi:“MI:0915”(physical association)	0.670
TFIP11	FAM13C	psi-mi:“MI:0915”(physical association)	0.670
KIF2A	FAM13C	psi-mi:“MI:0915”(physical association)	0.670
CCDC172	FAM13C	psi-mi:“MI:0915”(physical association)	0.670
FAM13C	TFIP11	psi-mi:“MI:0915”(physical association)	0.670
FAM13C	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
FAM13C	MTUS2	psi-mi:“MI:0915”(physical association)	0.560
FAM13C	HMBOX1	psi-mi:“MI:0915”(physical association)	0.560
FAM13C	PHC2	psi-mi:“MI:0915”(physical association)	0.560
FAM13C	CEP70	psi-mi:“MI:0915”(physical association)	0.560
DVL3	FAM13C	psi-mi:“MI:0915”(physical association)	0.560
FAM13C	SDCBP2	psi-mi:“MI:0915”(physical association)	0.560
MED4	FAM13C	psi-mi:“MI:0915”(physical association)	0.560
MEOX2	FAM13C	psi-mi:“MI:0915”(physical association)	0.560
MTUS2	FAM13C	psi-mi:“MI:0915”(physical association)	0.560
HMBOX1	FAM13C	psi-mi:“MI:0915”(physical association)	0.560
PHC2	FAM13C	psi-mi:“MI:0915”(physical association)	0.560
FAM13C	DVL3	psi-mi:“MI:0915”(physical association)	0.560
SDCBP2	FAM13C	psi-mi:“MI:0915”(physical association)	0.560
FAM13C	MED4	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (28): FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), FAM13C (Two-hybrid), CCDC172 (Two-hybrid), TUBA3C (Affinity Capture-MS), AHCYL2 (Affinity Capture-MS), AHCYL1 (Affinity Capture-MS)

ESM2 similar proteins: A0A5K7RLP0, A1YEX3, A2AGX3, A2AKB4, A7YWH3, A8MVX0, C9JSJ3, O08715, O88286, O88884, P24278, P97303, P97432, Q17RG1, Q1XFL1, Q3KNY0, Q3USH1, Q495C1, Q4V7B1, Q501R9, Q562E2, Q5SYB0, Q5VT97, Q5XIN1, Q6P2K3, Q6PCP7, Q6ZSG2, Q7TSX9, Q80SU3, Q80TL0, Q80W88, Q80XI1, Q8BLK9, Q8BSV3, Q8BW86, Q8K3E9, Q8K451, Q8N7W2, Q8NE31, Q8NFN8

Diamond homologs: A2AB59, A2RUV4, A6X8Z5, A7MB27, B1AUC7, B2RTY4, D2H9U0, E7F3F0, E9Q6X9, F1LQX4, F1LXF1, F4JI46, O14559, O43182, O54834, O94466, O94988, P11274, P15882, P30337, P34288, P42331, P46941, P85298, Q07960, Q10164, Q14CB8, Q17QN0, Q17R89, Q20498, Q2M1Z3, Q3KRB8, Q4LDD4, Q54BP9, Q54FF4, Q54FG5, Q54J98, Q54MV3, Q54TH9, Q54YV1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2440 predictions. Top by Δscore:

Variant	Effect	Δscore
10:59247735:CTT:C	acceptor_gain	1.0000
10:59247738:C:CC	acceptor_gain	1.0000
10:59251570:CATA:C	donor_loss	1.0000
10:59251571:ATAC:A	donor_loss	1.0000
10:59251572:TA:T	donor_loss	1.0000
10:59251573:A:C	donor_loss	1.0000
10:59251573:ACCTT:A	donor_gain	1.0000
10:59251574:C:CA	donor_loss	1.0000
10:59251574:CCTTC:C	donor_gain	1.0000
10:59251577:T:A	donor_gain	1.0000
10:59251672:CAGGC:C	acceptor_gain	1.0000
10:59251675:GCC:G	acceptor_loss	1.0000
10:59251676:CCT:C	acceptor_loss	1.0000
10:59251677:C:A	acceptor_loss	1.0000
10:59251677:C:CC	acceptor_gain	1.0000
10:59251679:A:C	acceptor_gain	1.0000
10:59252797:A:AC	donor_gain	1.0000
10:59252798:C:CC	donor_gain	1.0000
10:59252847:T:TA	donor_gain	1.0000
10:59253015:T:C	acceptor_gain	1.0000
10:59253015:T:TC	acceptor_gain	1.0000
10:59254346:A:AC	donor_gain	1.0000
10:59254347:C:CC	donor_gain	1.0000
10:59254347:CAA:C	donor_gain	1.0000
10:59254347:CAATT:C	donor_gain	1.0000
10:59254442:ACC:A	acceptor_loss	1.0000
10:59254443:CCTG:C	acceptor_loss	1.0000
10:59254444:C:A	acceptor_loss	1.0000
10:59254445:T:A	acceptor_loss	1.0000
10:59264167:C:CC	acceptor_gain	1.0000

AlphaMissense

3873 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:59247648:A:G	L575P	1.000
10:59247660:A:G	L571P	1.000
10:59247666:A:G	L569P	1.000
10:59247674:T:A	K566N	1.000
10:59247674:T:G	K566N	1.000
10:59247688:A:G	Y562H	1.000
10:59251623:C:G	R529P	1.000
10:59251634:C:A	K525N	1.000
10:59251634:C:G	K525N	1.000
10:59251656:A:G	L518P	1.000
10:59251668:A:G	L514P	1.000
10:59264165:G:T	P315H	1.000
10:59247648:A:T	L575H	0.999
10:59247662:T:A	R570S	0.999
10:59247662:T:G	R570S	0.999
10:59247663:C:G	R570T	0.999
10:59247673:C:G	A567P	0.999
10:59247675:T:A	K566I	0.999
10:59247676:T:C	K566E	0.999
10:59247683:C:A	K563N	0.999
10:59247683:C:G	K563N	0.999
10:59247685:T:C	K563E	0.999
10:59247688:A:C	Y562D	0.999
10:59247697:A:G	Y559H	0.999
10:59247716:C:A	R552S	0.999
10:59247716:C:G	R552S	0.999
10:59251604:A:C	F535L	0.999
10:59251604:A:T	F535L	0.999
10:59251606:A:G	F535L	0.999
10:59251614:A:G	L532S	0.999

dbSNP variants (sampled 300 via entrez): RS1000029602 (10:59313734 C>A), RS1000061792 (10:59304695 C>A,G,T), RS1000090949 (10:59262779 A>G), RS1000171782 (10:59306782 G>A), RS1000189183 (10:59348780 C>T), RS1000194464 (10:59325612 C>T), RS1000203116 (10:59307124 G>A,C), RS1000242173 (10:59255589 G>A), RS1000251930 (10:59258606 C>T), RS1000288804 (10:59266053 T>G), RS1000291578 (10:59342042 C>A,T), RS1000293139 (10:59255970 T>C,G), RS1000309079 (10:59326265 T>C), RS1000328566 (10:59278843 C>G), RS1000332262 (10:59343304 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001834_9	Oleic acid (18:1n-9) levels	5.000000e-06
GCST002932_31	Manganese levels	2.000000e-06
GCST003518_34	Daytime sleep phenotypes	4.000000e-06
GCST011742_59	Triglyceride levels in HIV infection	5.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007828	daytime rest measurement
EFO:0004530	triglyceride measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression	6
Benzo(a)pyrene	affects methylation, decreases expression, increases expression	4
trichostatin A	affects cotreatment, increases expression	3
Cyclosporine	decreases expression, increases methylation	3
mercuric bromide	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Formaldehyde	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
tris(2-butoxyethyl) phosphate	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1
jinfukang	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Cisplatin	increases expression, affects cotreatment	1
Dactinomycin	affects cotreatment, increases expression	1
Demecolcine	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Gallic Acid	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Nickel	decreases expression	1
Quercetin	decreases expression	1
Dihydrotestosterone	increases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	decreases expression	1
Urethane	decreases expression	1
Vincristine	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer